TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Executive Summary

• TempraMed Technologies Ltd. signed an exclusive three-year distribution agreement with Mobil Saúde Comercial Ltda to commercialize its temperature-sensitive medication storage products in Brazil.
• The partnership includes minimum annual purchase commitments, with exclusivity contingent upon the placement and full prepayment of an initial order.
• The agreement aligns with TempraMed's Latin American expansion strategy and follows the recent grant of a Brazilian patent for its VIVI Box™ platform, while the company also initiated a €100,000 European investor relations program.

Key Details

• Distribution Agreement: Exclusive three-year framework with Mobil Saúde Comercial Ltda for the Brazilian market.
• Product Portfolio: Initial distribution will feature VIVI Cap™, with potential future inclusion of VIVI Med™, VIVI Epi™, and VIVI Cap Smart™ as the partnership develops.
• Commercial Terms: Exclusivity becomes effective only after placement and full prepayment of the initial order. The agreement includes minimum annual purchase commitments.
• Market Context: Brazil's diabetes market reached USD $2.15 Billion in 2025 and is projected to surpass USD $3.09 Billion by 2034 (CAGR 3.96%), driven by demand for temperature-sensitive therapies including insulin, GLP-1s, biologics, and epinephrine auto-injectors.
• Intellectual Property: The Brazilian Patent Office recently granted TempraMed a patent covering core VIVI Box™ innovations, protecting thermal-insulation, smart-monitoring, portable cold storage, and cloud-connected monitoring capabilities through October 2039.
• Product Launch Timeline: VIVI Box™ is expected to launch commercially at the end of 2026.
• Investor Relations/Marketing: As of May 28, 2026, TempraMed engaged Plutus Invest & Consulting GmbH for a 12-month European investor program (subject to CSE approval). The company agreed to pay €100,000 immediately for the entirety of the program. Plutus is at arm's length from TempraMed.

Notable Quotes

• "This agreement represents an important milestone in our expansion strategy across Latin America," said Ron Nagar, CEO of TempraMed. "Brazil is one of the world's largest and most strategically important markets for diabetes care and injectable therapies. Partnering with Mobil Saúde has the potential to significantly expand access to our products while strengthening our commercial presence in the region."